Value-based medicine: A new paradigm to evaluate treatments for vitreoretinal diseases and other medical interventions

International Ophthalmology Clinics

Volumn 44, Issue 4, 2004, Pages 155-172

  Busbee, Brandon G ^c   Brown, Gary C ^a   Brown, Melissa M ^b  

^a Retinavitreous Associates   (United States)

^b CENTER FOR VALUE BASED MEDICINE   (United States)

^c OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE;

CLINICAL TRIAL; CODING; COST UTILITY ANALYSIS; DECISION THEORY; DIABETIC MACULAR EDEMA; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETINA MACULA EDEMA; REVIEW; TREATMENT OUTCOME; VALUE BASED MEDICINE; VITREORETINOPATHY;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EYE DISEASES; HEALTH CARE COSTS; HUMANS; RETINAL DISEASES; VITREOUS BODY;

EID: 6344225683     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404440-00012     Document Type: Review

References (74)

1. U.S. Census Bureau. Health Insurance Coverage 2002. Available at: http://www.census.gov/hhs. Accessed April 2004.
2. World Health Organization. World Health Organization Report 2000. Available at: http://www.who.int/en/. Accessed April 2004.
3. Oregon Measure 23. Available at: http://healthcareforalloregon.org. Accessed April 2004.
4. Center for Medicare & Medicaid Services. National Health Expenditures and Selected Economic Indicators, Levels and Average Annual Percent Change: Selected Calendar Years 1980-2012. Available at: http://cms.hhs.gov. Accessed April 2004.
5. Brown GC, Brown MM, Sharma S. Value-based medicine: evidence-based medicine and beyond. Ocul Immunol Inflamm. 2003;11:157-170.
6. Brown MM, Brown GC, Sharma S. Value-based medicine and vitreoretinal diseases. Curr Opin Ophthalmol. 2004;15:167-172.
7. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48:204-223.
8. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268:2420-2425.
9. Finkelstein D. Argon laser photocoagulation for macular edema in branch vein occlusion. Ophthalmology. 1986;93:975-977.
10. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995;113: 1479-1496.
11. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol. 1986; 104:694-701.
12. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol. 2001;119:198-207.
13. Beauchamp GR, Bane MC, Stager DR, et al. A value analysis model applied to the management of amblyopia. Trans Am Ophthalmol Soc. 1999;97:349-367, discussion 367-372.
14. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473-511.
15. Brown GC, Brown MM, Sharma S, et al. Cost-effectiveness of treatment for threshold retinopathy of prematurity. Pediatrics. 1999;104:e47.
16. Brown MM, Brown GC, Sharma S, et al. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128:324-330.
17. Brown GC, Brown MM, Sharma S, et al. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14:18-24.
18. Brown GC, Brown MM, Sharma S, et al. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology. 2000;107: 1374-1380.
19. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis. Retina. 2000;20:331-337.
20. Brown GC, Sharma S, Brown MM, et al. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000;118:47-51.
21. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283:889-896.
22. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85:327-331.
23. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2001;108:2051-2059,
24. Sharma S, Hollands H, Brown GC, et al. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol. 2001;12:230-234.
25. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiol. 2002;9: 1-10.
26. Brown GC, Brown MM, Sharma S, et al. A cost-utility analysis of interventions for severe proliferative vitreoretinopathy. Am J Ophthalmol. 2002;133:365-372,
27. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473-511. Am J Ophthalmol. 2000;129:833.
28. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473-511. Am J Ophthalmol. 2000;129:833.
29. Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. Primary Care. 1995;22:271-280.
30. Rothwell PM, McDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. Br Med J. 1997;314:1580-1583.
31. Brown GC, Brown MM, Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol. 2000;35:127-133.
32. Kassirer JP. Adding insult to injury. Usurping patients' prerogatives. N Engl J Med. 1983; 308:898-901.
33. Angell M. Patients' preferences in randomized clinical trials. N Engl J Med. 1984;310: 1385-1387.
34. Lunde IM. Patients' perceptions - a shift in medical perspective. Scand J Prim Health Care. 1993;11:98-104.
35. Landy J, Stein J, Brown MM, et al. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit. 2002;8:CR543-CR548.
36. Stein JD, Brown MM, Brown GC, et al. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol. 2003;87: 8-12.
37. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40:593-603.
38. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5:559-575.
39. Weinstein MC SW. Foundations of cost-effectiveness analysis for health and medical practice. N Engl J Med. 1977;296:716-721.
40. Brown GC, Brown MM, Sharma S. Cost-utility analysis. Ann Intern Med. 2001;134: 625-626.
41. Wyatt JR, Niparko JK, Rothman M, et al. Cost utility of the multichannel cochlear implants in 258 profoundly deaf individuals. Laryngoscope. 1996;106:816-821.
42. Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. AJNR Am J Neuroradiol. 1997;18:1453-1462.
43. Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med. 1997;167:1972-1980.
44. Smith KJ, Roberts MS. Antiviral therapies for herpes zoster infections. Are they economically justifiable? Pharmacoeconomics. 2000;18:95-104.
45. Busbee BG, Brown MM, Brown GC, et al. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology. 2002;109:606-612, discussion 612-613.
46. Membreno JH, Brown MM, Brown GC, et al. A cost-utility analysis of therapy for amblyopia. Ophthalmology. 2002;109:2265-2271.
47. Spath MA, O'Brien BJ. Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death. Pharmacoeconomics. 2002;20:727-738.
48. Busbee BG, Brown MM, Brown GC, et al. Cost-utility analysis of cataract surgery in the second eye. Ophthalmology. 2003;110:2310-2317.
49. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276: 1172-1177.
50. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
51. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765-772.
52. Chen SD, Lochhead J, Patel CK, et al. Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol. 2004;88:154-1515.
53. Conway MD, Canakis C, Livir-Rallatos C, et al. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003; 29:27-33.
54. Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol. 2003;87:361.
55. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol. 2003;136:384-386.
56. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye. 2004;Apr 23 (Epub).
57. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57-61.
58. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol. 2001;119: 1380-1383.
59. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
60. Sutter FK, Gillies MC. Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol. 2003;121:1491-1493.
61. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
62. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol. 2003;87:972-974.
63. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 1999;27:431-432.
64. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003;121:1279-1282.
65. Parke DW. Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol. 2003;136: 918-919.
66. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol. 2003;121:1663-1664.
67. The Macugen Collaborative Trial. Phase 3 for Protocol EOP1008. Anaheim, CA: American Academy of Ophthalmology; 2003.
68. Treeage. Data TM 3.5 Healthcare User's Manual. Williamstown, MA: Treeage Software, Inc; 1999.
69. CDC. Life Expectancy at Birth, at 65 Years of Age, and at 75 Rears of Age, According to Race and Sex: United States, Selected Years 1900-2001. Available at: http://www.cdc.gov. Accessed April 2004.
70. Prescription Price Guide. Available at: http://www.harvardpilgrim.com. Accessed April 2004.
71. A Guide for Anesthesia Values. Park Ridge, IL: Relative Value Guide; 2001.
72. Busbee BG, Brown GC, Brown MM. Cost-effectiveness of ocular interventions. Curr Opin Ophthalmol. 2003;14:132-138.
73. Brown GC, Brown MM, Sharma S. Health care in the 21st century: evidence-based medicine, patient preference-based quality, and cost effectiveness. Qual Manag Health Care. 2000;9:23-31.
74. Brown GC, Brown MM, Sharma S. Value-based medicine. Surv Ophthalmol. 2004. In press.